28/05/2019 19:44:28

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against American Renal Associates Holdings, Inc.

LOS ANGELES, May 28, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 28, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of American Renal Associates Holdings, Inc. (“American Renal” or the “Company”) (NYSE: ARA) investors who purchased securities between August 10, 2016 and March 27, 2019, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

On March 8, 2019, American Renal disclosed that in October 2018 the U.S. Securities and Exchange Commission (“SEC”) had requested documents and information regarding revenue recognition, collections, and other related matters. Also, the Company announced that it would delay filing its 2018 annual report while the Audit Committee investigated the Company’s revenue recognition methods and accounting practices.

On this news, shares of American Renal fell $2.05 per share, or more than 16%, to close at $10.46 per share on March 8, 2019, thereby injuring investors.

Then, on March 27, 2019, American Renal announced that certain financial statements would be restated and that its Chief Financial Officer had resigned. The Audit Committee found that the Company “did not appropriately reconcile its contractual allowance estimates for discounts and price concessions with cash subsequently received in respect of prior period patient claims.” The Company also disclosed that the required adjustments would reduce operating income for fiscal 2017 by at least $10 million and would have a cumulative impact on fiscal years 2014 to 2018 in the range of negative $5 million to positive $5 million. Furthermore, the Company stated that it expected to revise related metrics “such as revenue per treatment and days sales outstanding” during the affected financial periods based on the Audit Committee’s ongoing review.

On this news, shares of American Renal fell $3.69 per share, or 38%, to close at $6.01 per share on March 28, 2019, thereby further injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal’s accounting process for revenue recognition, collections, and related matters would give rise to an SEC investigation into the same, and increased regulatory scrutiny by the SEC; (2) American Renal's financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018 were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired American Renal securities during the Class Period you may move the Court no later than May 28, 2019 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles

Lesley Portnoy, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

GPM Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
23 Aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
42
25 Aug
VELO
Det er interessant at kigge på Veloxis vækst og nuværende position i markedet for at regne frem til ..
39
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
21
22 Aug
 
Jeg synes hun gjorde det fremragende i sagen om Grønland og Trump.   Det vigtigste i en sådan situat..
20
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
24 Aug
GOMX
Har aktien:   GOMSPACE: TECKNAR AVTAL MED ESA VÄRT 1,4 MLN EUR 19:26STOCKHOLM (Nyhetsbyrån Direkt) R..
15
23 Aug
VELO
Netop i denne måned har jeg været på EuroInvestor i 1 år og manglede, for at sige det mildt, baggrun..
15
20 Aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15
23 Aug
PNDORA
@Fqvist1 - ser er du er short fra 257, jf. din orientering d. 20.08. Jeg vil gerne gentage udbygge m..
14

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Maha Energy AB (publ) (“Maha” or the “Company”) Announces Filing of Second Quarter Report and Live Webcast
2
Texas Clinic of Chiropractic Declares Its Grand Opening in New Braunfels, Texas
3
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Acer Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
4
PRF: Consolidated Unaudited Interim Report of AS PRFoods for the 4th quarter and 12 months of 2018/2019 financial year
5
Acron Group’s H1 2019 IFRS Net Profit Increases Five Fold to USD 263 Million

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 August 2019 11:02:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB5 - 2019-08-26 12:02:48 - 2019-08-26 11:02:48 - 1000 - Website: OKAY